2,500
Participants
Start Date
April 8, 2024
Primary Completion Date
December 30, 2026
Study Completion Date
December 30, 2027
Treatment of seropositive individuals (positive serology test, but parasitology not confirmed)
Subjects agreeing to participate in the study and matching the inclusion/exclusion criteria will receive acoziborole 960 or 640 mg in a single intake at study day 1. Following treatment, participants will attend follow-up visits at home or at the study centre at 3 days and 3-months post treatment.
Institute of Tropical Medicine, Belgium
OTHER
Institut de Recherche pour le Developpement
OTHER_GOV
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo
OTHER
Ministry of Public Health, Democratic Republic of the Congo
OTHER_GOV
Drugs for Neglected Diseases
OTHER